AbbVie Posts 3Q EPS of $2.37
ABBV sits 58% above its 52-week low of $190.75.
Summary
AbbVie reported third-quarter EPS of $2.37 and net income of $4.22B in a Dow Jones Newswires flash. The EPS figure compares with diluted EPS of $2.03 in Q2, when revenue rose 10% to $16.99B on Skyrizi and Rinvoq growth. The headline carries no revenue, guidance, or year-ago comparison, so the beat/miss picture is not yet clear. Shares sit near the 52-week high, so the bar for this print is high. Full Q3 release details and any guidance update will determine direction.
At the time of this announcement, ABBV was trading at $301.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $513.9B. The 52-week trading range was $190.75 to $292.67. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.